Background: Reactive oxygen species modulator 1 (ROMO1) is recognized to be involved in cell proliferation and is elevated in serum of various cancer patients.
| INTRODUC TI ON
Pleural effusion is a clinical symptom often secondary to a variety of diseases, especially kinds of cancer and tuberculosis, known as typical malignant pleural effusion (MPE) and tuberculous pleural effusion (TPE) 1, 2 ; sometimes, it also happens after a lung infection.
Among them, the most common source of the MPE is lung cancer.
Some studies have shown that among 840 causes of MPE, which due to lung cancer accounted for about 37% of the total, most of them were lung adenocarcinoma (50%). 3 Lung cancer is recognized as highly aggressive and metastatic, ranking second in the world in cancer incidence. Research shows that about 1.8 million sufferers are diagnosed with lung cancer and almost 1.6 million die of the disease every year 4 ; moreover, it is also the principal cause of cancer death worldwide. 5 The nonsmall-cell lung cancer (NSCLC) is the commonest type of lung cancer and accounts for a largest proportion of the total (85%), 6 including squamous cell carcinoma, large cell lung cancer, and adenocarcinoma. The treatment effect is poor, and the 5-year survival rate is lower than 15%. 7 Because the clinical symptoms of lung cancer are usually more clinically relevant in the late stage, most patients are already in advanced stage at diagnosis and have a poor prognosis. Therefore, early diagnosis of lung cancer is a valuable way to improve the prognosis of patients. However, regular sputum cytology and chest imaging examinations did not show significant advantages. 8 Thoracoscopy is a good way to diagnose lung cancer with a sensitivity of up to 90%. 9 However, because it is an invasive examination, the patient's acceptance is low, the operation is complicated, and the risk is high, and it is not suitable as a method for screening and diagnosing lung cancer. On the other hand, pleural effusion is one of the clinical manifestations of lung cancer patients. Differential diagnosis of MPE is also one of the ways to diagnose lung cancer. Cytology is the golden standard for distinguishing the nature of pleural fluid; however, the positive rate is not high (11% ~ 78%). 10 For the past few years, scientific research personnel had been struggling to quest suitable pleural effusion markers to identify the properties of pleural effusion.
Currently, commonly used markers in pleural fluid include such as pLDH, pFER, pCA199, pCA125, pCA153, pADA, but the above markers have the shortcomings such as the low sensitivity and/or specificity for detecting MPE.
Reactive oxygen species modulator 1 (ROMO1) is a novel protein selected from human complementary DNA (cDNA) library. 11 Reactive oxygen species modulator 1 can induce the production of intracellular reactive oxygen species (ROS), while ROS can promote cell proliferation, 12 many studies had shown that the level of ROMO1 is up-regulated in many cancers 13, 14 ; during the past several years, increasingly articles on the expression levels of ROMO1 in tissues and various body fluids and various The relationship between the diseases, 15, 16 and other studies have shown that ROMO1 is also related to the prognosis and drug resistance of cancer. 17, 18 The aim of our research was to inquire into the feasibility of using ROMO1 and several conventional biomarkers in the differential diagnosis of MPE derived from NSCLC, and the correlation between several others clinical indicators of NSCLC patients.
| MATERIAL S AND ME THODS
The pleural fluid samples were gathered from 116 inpatients in the First Affiliated Hospital of Wenzhou Medical University, China, from August 2018 to March 2019.
| Sample selection and grouping
The transudates specimens were excluded by detecting the spe- 
| Collection and detection of pleural effusion
We gathered about 10 mL pleural fluid from above patients by 
| Statistical analysis
Shapiro-Wilk test is used to assess the distribution of the data we have obtained. Comparisons between the two teams were made using t test or Mann-Whitney U test. The chi-square test was used to evaluate the difference between the categorical variables. P < .05 was statistical significance. Analyze the receiver operating characteristic curves (ROC), and the area under the ROC curve (AUC) was used to assess the performance of the subject.
All of the above statistical analyses were processing by MedCalc (MedCalc Software) and SPSS 23.0 (Statistical Package for the Social Sciences Corporation).
| RE SULTS

| Differences in parameters between MPE and BPE groups
The data distribution of all parameters was detected by Shapiro-Wilk test, and as a result, all the laboratory test data were proved as non-normal distribution; therefore, the data were subsequently analyzed using Mann-Whitney U test. The concentration of ROMO1, pCA125, pCA199, pCA153, pADA + ROMO1, pCA153 + ROMO1, pCA125 + ROMO1, and pCA199 + ROMO1 in the MPE was obviously higher compared with BPE team (Mann-Whitney U = 828.000, 823.000, 590.500, 472.500, 235.000, 413.000, 665.000, 617.000,
The P value of all the above items is .000). The pADA concentration of BPE team was distinctly higher in comparison with the other group (Mann-Whitney U test = 494.000, P = .000). The pFER and pLDH values of the MPE group show no significant differences comparison between the BPE group (P = .226, .749) (see Figure 1 and Table 1 ).
| Diagnostic efficacy of various parameters for MPE
The ROC curve shows the sensitivities of ROMO1, pCA125, pCA199, pCA153, pADA, pADA + ROMO1, pCA153 + ROMO1, pCA125 + ROMO1, and pCA199 + ROMO1 for MPE were 52%, 71.83%, 63.01%, 67.61%, 96%, 98.67%, 66.2%, 50.7%, and 56.16%, respectively, and the specificities of those markers for the diagnosis of MPE were 82.93%, 58.97%, 94.87%, 94.87%, 70.73%, 70.73%, 92.31%, 97.44%, and 89.74%. The AUC of those parameters was, respectively, 0.706, 0.720, 0.754, 0.831, 0.09, 0.941, 0.842, 0.762, and 0.777. We found that when combined assay ROMO1 and pADA, the AUC (0.941) was the highest among whole parameters, when the cutoff value is 0.38 the sensitivity (98.67%) was higher than other indicators, and the specificity (70.73%) was the same as pADA (see Figure 2 and Table 2 ).
F I G U R E 1
Comparison of the parameters of the two groups of pleural effusion showed that the levels of ROMO1, pCA125, pCA199, and pCA153 in the MPE group were significantly higher than those in BPE. In addition, the pADA level of the BPE group also showed a significant increase compared with the MPE. ***P < .001 
TA B L E 1 Comparison of the parameters in pleural effusion in the MPE and BPE groups
| Relevancy between ROMO1 and clinical information of NSCLC patients
We investigated age, gender, lymph node involvement, distant metastasis, tumor histological types, and smoking status in patients with NSCLC related to ROMO1 expression levels. Their relationship is summarized in Table 3 . It shows that in our study, the expression level of ROMO1 in pleural effusions of NSCLC patients was not significantly different from age range (P = .051), gender (P = .229), smoking status (P = .185), tumor histology type (P = .065), and lymph node involvement (P = .905), but was associated with distant metastasis of tumors (P = .033). Then, the ROC curve shows that its AUC is 0.667, and the cutoff value = 34.1 ng/ mL, and the sensitivity and specificity are 63.16% and 83.3%, respectively (see Figure 3 ).
| D ISCUSS I ON
In China, pleural fluid is a clinically relevant symptom. The major diseases which cause of this symptom are carcinoma of lungs (especially NSCLC) and tuberculosis. The treatment and prognosis of the two diseases are quite different, and some studies show that lung cancer-related hydrothorax was related to the prognosis of the patient. 19 Thus, the identification of the nature of exudative pleural effusion is very important. Conventional histopathology and pleural cytology are the gold criteria for distinguishing between malignant and benign pleural effusions, but its low sensitivity limits its clinical utility. Therefore, the problem of how to improve the differentiate of pleural effusion was still researchable. In this study, we examined routine markers for pleural effusion and a less well-documented marker, ROMO1, to explore new markers that could be used to distinguish the nature of pleural effusions.
Reactive oxygen species modulator 1 is a membrane protein discovered in 2006, located in the mitochondria, capable of controlling the production of its intracellular ROS, 11 thereby affecting cell proliferation. 12 Studies have shown that the concentration of ROMO1 in serum of lung cancer patients is significantly higher than normal people. 14 In addition, cells lacking ROMO1 are more sensitive to the effects of apoptosis. 20 To date, many studies have shown that ROMO1 expression is specifically elevated to a variety of diseases accompanied with high oxidative stress and inflammation. 15, 21 Adenosine deaminase is known as an important enzyme which could catalyze the conversion to adenosine to inosine and is widely distributed among humans. ADA high activity is associated with T lymphocyte subsets involved in tuberculosis-induced inflammatory responses. 22, 23 To date, many studies have shown the potential for ADA levels in effusions to diagnose tuberculous serous effusions, including pleural effusions, peritoneal effusion, and pericardial effusion. 24 In addition, some researchers have discovered that pleural effusion can be used as one of the indicators for distinguishing between NSCLC-related MPEs. 25 The AUC forecasts the veracity of the diagnostic test. The diagnostic value was poor if AUC is between 0.5 and 0.7, and the diagnostic value is higher when AUC > 0. 8 
